Drug Profile
Octreotide implant - Endo Pharmaceuticals Solutions
Alternative Names: VP 003Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Valera Pharmaceuticals
- Developer Endo Pharmaceuticals Solutions
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acromegaly; Malignant carcinoid syndrome
Most Recent Events
- 11 Nov 2011 Discontinued - Phase-III for Acromegaly in Czech Republic (SC)
- 11 Nov 2011 Discontinued - Phase-III for Acromegaly in Germany (SC)
- 11 Nov 2011 Discontinued - Phase-III for Acromegaly in Hungary (SC)